| Jun 27 |
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
|
| Jun 14 |
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
|
| Jun 4 |
Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
|
| May 30 |
Monte Rosa Therapeutics promotes Champoux to COO
|
| May 30 |
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
|
| May 30 |
Monte Rosa Therapeutics Announces Leadership Team Promotions
|
| May 21 |
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
|
